A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult.

Thundon Ngamprasertchai,Chayanis Kositamongkol,Saranath Lawpoolsri,Pinyo Rattanaumpawan,Viravarn Luvira,Piriyaporn Chongtrakool,Jaranit Kaewkungwal,Kulkanya Chokephaibulkit,Pochamana Phisalprapa

Frontiers in public health（2023）

引用 0|浏览5

暂无评分

摘要

In the context of Thailand, PCV13 is recommended as the best buy and should be primarily prioritized when both costs and benefits are considered. Also, this model will be beneficial to the two-next generation pneumococcal vaccines implementation in Thailand.

查看译文

关键词

pneumococcal polysaccharide vaccine,cost-effectiveness cost-effectiveness analysis,thai

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要